Skip to main content
Gynecologic Oncology Reports logoLink to Gynecologic Oncology Reports
. 2020 May 28;33:100590. doi: 10.1016/j.gore.2020.100590

Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]

Alessandro D Santin a,, Virginia Filiaci b, Stefania Bellone a, Roisin O'Cearbhaill k, Elena S Ratner a, Cara A Mathews c, Guilherme Cantuaria d, Camille C Gunderson e, Teresa Rutledge f, Barbara M Buttin g, Heather A Lankes h,i, Michael J Birrer j
PMCID: PMC7452617  PMID: 32885014

The authors regret that the authorship of this article was published incorrectly. The above author details are correct, and the online version has been updated.

The authors would like to apologise for any inconvenience caused.

Contributor Information

Alessandro D. Santin, Email: alessandro.santin@yale.edu.

Virginia Filiaci, Email: FiliaciV@NRGOncology.org.

Stefania Bellone, Email: Stefania.bellone@yale.edu.

Elena S. Ratner, Email: elena.ratner@yale.edu.

Cara A. Mathews, Email: cmathews@wihri.org.

Guilherme Cantuaria, Email: Guilherme.Cantuaria@northside.com.

Camille C. Gunderson, Email: Camille-Gunderson@ouhsc.edu.

Teresa Rutledge, Email: TRutledge@salud.unm.edu.

Barbara M. Buttin, Email: Barbara.Buttin@nm.org.

Heather A. Lankes, Email: LankesH@NRGOncology.org.

Michael J. Birrer, Email: mbirrer@uab.edu.


Articles from Gynecologic Oncology Reports are provided here courtesy of Elsevier

RESOURCES